Accolade’s Hold Rating Affirmed Amid Conservative Outlook and Adjusted Financial Estimates
Analyst Craig Hettenbach of Morgan Stanley maintained a Hold rating on Accolade (ACCD – Research Report), with a price target of $12.00.
Analysts Offer Insights on Healthcare Companies: Accolade (ACCD), Vertex Pharmaceuticals (VRTX) and Zimmer Biomet Holdings (ZBH)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Accolade (ACCD – Research Report), Vertex ...
Caitlin Clark makes more history as she notches another accolade
Indiana Fever No. 1 pick Caitlin Clark made history on Tuesday night when she was named the winner of the James E. Sullivan ...
Accolade: Fiscal Q4 Earnings Snapshot
SEATTLE — SEATTLE — Accolade, Inc. (ACCD) on Thursday reported a loss of $7.5 million in its fiscal fourth quarter. The Seattle-based company said it had a loss of 10 cents per share. The results ...
Kylie Kelce Reveals Sweet Retirement Gift She Got for Husband Jason Kelce
Kylie Kelce commemorated her husband Jason Kelce's retirement from the NFL with the most thoughtful and personalized gift.